Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Cadila Healthcare Ltd    CADILAHC   INE010B01027

CADILA HEALTHCARE LTD (CADILAHC)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Cadila Healthcare : gets Mexico regulator approval for Lipaglyn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:58pm CEST

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. Zydus today announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipagly (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).

"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia", said Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. The scrip opened at Rs 476 and has touched a high and low of Rs 478 and Rs 464.5 respectively.

(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CADILA HEALTHCARE LTD
09/17KRAFT HEINZ : Buzz of coke picking complan gets louder
AQ
09/17CADILA HEALTHCARE : Not many pain-points
AQ
09/11CADILA HEALTHCARE : Zydus Cadila gets tentative nod from USFDA for diabetes drug
AQ
09/06CADILA HEALTHCARE : Zydus Cadila gets USFDA nod for antiviral drug
AQ
09/06CADILA HEALTHCARE : receives USFDA approval for Acyclovir Sodium Injection
AQ
09/06CADILA HEALTHCARE : Zydus Cadila gets USFDA nod to sell herpes viruses treatment..
AQ
09/04CADILA HEALTHCARE : up for third straight session
AQ
08/31CADILA HEALTHCARE : Zydus Cadila gets USFDA nod to market 2 products
AQ
08/27CADILA HEALTHCARE : Biologics manufacturing facility successfully completes USFD..
AQ
08/21Hindustan Construction Company Ltd leads gainers in `A` group
AQ
More news
Financials (INR)
Sales 2019 126 B
EBIT 2019 23 409 M
Net income 2019 18 796 M
Debt 2019 21 290 M
Yield 2019 0,96%
P/E ratio 2019 21,39
P/E ratio 2020 18,86
EV / Sales 2019 3,37x
EV / Sales 2020 2,98x
Capitalization 403 B
Chart CADILA HEALTHCARE LTD
Duration : Period :
Cadila Healthcare Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CADILA HEALTHCARE LTD
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 35
Average target price 427  INR
Spread / Average Target 8,5%
EPS Revisions
Managers
NameTitle
Sharvil Pankajbhai Patel Managing Director & Executive Director
Pankaj Ramanbhai Patel Non-Executive Chairman
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Humayun Raja Dhanrajgir Independent Non-Executive Director
Sector and Competitors